The global AI in pharmaceutical market is experiencing an unprecedented growth trajectory, with a projected valuation of US$4,451.6 Mn by 2030, marking a substantial rise from approximately US$807.2 Mn in 2018. This extraordinary expansion is attributed to the pervasive adoption of Artificial Intelligence (AI) across the pharmaceutical industry, driving innovation in drug discovery, development, and personalized healthcare.
Read More: https://www.fairfieldmarketresearch.com/report/ai-in-pharmaceutical-market
Between 2023 and 2030, the market is set to realize an impressive Compound Annual Growth Rate (CAGR) of 19.1%, symbolizing AI's transformative influence on the pharmaceutical sector.
A New Era in Pharmaceutical Advancements
The integration of AI into the pharmaceutical industry heralds a new era of innovation, enabling researchers and healthcare professionals to make data-driven decisions, reduce costs, and improve patient outcomes. This paradigm shift is revolutionizing drug discovery and development, making it more efficient and effective.
Key Market Insights
AI is emerging as a catalyst for change in drug discovery and development, harnessing data analytics, machine learning, and natural language processing. By accelerating research processes, AI significantly reduces costs and enhances the likelihood of developing effective medications. As AI technologies continue to evolve, their role in reshaping the pharmaceutical sector becomes increasingly prominent.
The global AI in pharmaceutical market is projected to reach US$4,451.6 Mn by 2030, surging from US$807.2 Mn in 2018. The increasing use of AI in drug discovery and development, predictive forecasting, pharmaceutical marketing, and personalized treatment are pivotal drivers of this growth. Asia Pacific is positioned to be the fastest-growing market, with North America maintaining a leading position. 3. Driving Factors
Increased Potential in New Drug Discovery AI has become indispensable in the pharmaceutical sector, especially in the context of the COVID-19 pandemic. It aids in identifying disease patterns with precision, leading to the discovery of optimal drug compositions. Embracing AI reduces research and development costs, minimizes errors, and accelerates drug development, resulting in affordable and efficacious medicines.
Rapid Adoption of AI in Drug Discovery and Development AI is increasingly central to drug discovery and development. It analyzes vast datasets to identify potential drug targets, optimize drug molecules, and predict efficacy and safety. AI also plays a pivotal role in identifying biomarkers for personalized treatment and expediting drug development.
Thriving Advanced Technology-Enabled Personalized Treatment AI empowers healthcare professionals to provide personalized treatment through real-time patient data analysis. Machine learning and AI-driven data analysis offer early insights into patient conditions, enhancing diagnostic capabilities. Predictive forecasting, clinical trial optimization, and pharmaceutical marketing also reap benefits from AI, propelling market growth.
Drug Discovery: Pioneering the Transformation The drug discovery segment is a major contributor to the AI in pharmaceutical market, valued at US$291.7 Mn in 2022 and projected to reach approximately US$1,225.9 Mn by 2030. AI's influence in drug discovery spans target identification, clinical trials, and molecular pathway analysis, resulting in significantly improved efficiency and success rates.
Natural Language Processing: Dominant Technology Segment Natural language processing (NLP) is a critical technology in the pharmaceutical industry, enabling the extraction, organization, and analysis of unstructured text data. NLP expedites the identification of drug candidates, targets, and biological pathways, accelerating drug discovery.
North America Leads the Way North America, a global technology hub, is expected to hold a substantial share in the AI in pharmaceutical market. AI applications in clinical trials, drug discovery, and drug development, combined with the growing burden of chronic diseases, are driving market growth. Industry leaders and cross-industry collaborations further bolster the region's position.
The United States Takes the Lead in Investment Global investment in AI in the pharmaceutical industry is surging, with the United States at the forefront. Investment is projected to reach US$6.3 Bn by 2025, with nearly half of the total coming from the US. China, the UK, Germany, France, and Japan are also actively investing in AI to enhance drug discovery and development capabilities.
Asia Pacific: The Fastest Growing Region The Asia Pacific region is experiencing rapid growth, with a CAGR of 20.8%. AI adoption in the pharmaceutical industry is gaining momentum, particularly in countries like China, Japan, India, and South Korea. AI is accelerating drug discovery, optimizing drug designs, and tailoring treatment plans to individual patients' characteristics. The region's focus on precision medicine and AI-driven drug repurposing further fuels growth.
The AI in pharmaceutical market is marked by intense competition, with companies and research institutions leveraging AI to advance drug discovery, development, and patient care. Key players include GNS Healthcare, Benevolent AI, Berg Health, Novo Nordisk, IBM Corporation, Alphabet Inc (DeepMind), General Electric Company, Pfizer Inc., Johnson & Johnson, and Novartis AG.
Our Trending Blogs:
Fairfield Market Research
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746